Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01123005 · ClinicalTrials.gov registry record · Phase 1
Imaging and Biomarkers of Hypoxia in Solid Tumors
A Phase 1 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT01123005: Clinical Trial Phase 1 study, sponsored by Stanford University.
NCT01123005 is a Phase 1 study that was terminated before completion, run by Stanford University. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01123005, a Phase 1 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
Hypoxia, meaning a lack of oxygen, has been associated strongly with a wide range of human cancers. Hypoxia occurs when tumor growth exceeds the ability of blood vessels to supply the tumor with oxygenated blood. It is currently understood that hypoxic tumors are more aggressive. Current methods for measuring hypoxia include invasive procedures such as tissue biopsy, or insertion of an electrode into the tumor. EF5-PET may be a non-invasive way to measure tumor hypoxia.
Interventions
- DRUG Dichloroacetate
- DRUG EF5
- PROCEDURE PET Scan
- DRUG Carbogen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2010-12 |
| Est. Completion | 2015-08-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01123005
The ClinicalTrials.gov registry entry for NCT01123005 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dichloroacetate is the first listed.
NCT01123005 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01123005 about?
NCT01123005 is a clinical study titled "Imaging and Biomarkers of Hypoxia in Solid Tumors". Hypoxia, meaning a lack of oxygen, has been associated strongly with a wide range of human cancers. Hypoxia occurs when tumor growth exceeds the ability of blood vessels to supply the tumor with oxygenated blood. It is currently understood that hypoxic tumors are more aggressive. Current methods for...
What is the current status of trial NCT01123005?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2010-12. Estimated completion is 2015-08-21.
What interventions are being tested in trial NCT01123005?
The interventions under investigation include: Dichloroacetate (DRUG), EF5 (DRUG), PET Scan (PROCEDURE), Carbogen (DRUG).
Who is sponsoring clinical trial NCT01123005?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.